Loading...
XNAS
CDXS
Market cap232mUSD
Jul 10, Last price  
2.47USD
1D
-1.54%
1Q
14.29%
Jan 2017
-44.35%
IPO
-81.77%
Name

Codexis Inc

Chart & Performance

D1W1MN
XNAS:CDXS chart
P/E
—
P/S
3.19
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.98%
Rev. gr., 5y
0.38%
Revenues
70m
+18.61%
12,127,00025,333,00050,478,00082,908,000107,104,000123,865,00088,298,00031,922,00035,307,00041,804,00048,837,00050,024,00060,594,00068,458,00069,056,000104,754,000138,590,00070,143,00059,345,00070,387,000
Net income
-44m
L-32.63%
-18,671,000-38,977,000-45,127,000-20,289,000-8,541,000-16,550,000-30,857,000-41,303,000-19,071,000-7,581,000-8,558,000-22,996,000-10,878,000-11,935,000-24,010,000-21,279,000-33,592,000-76,240,000-65,276,000-43,974,000
CFO
-19m
L-60.79%
-13,287,000-6,470,000-36,316,000-8,686,000-16,383,000-490,000-11,892,000-22,998,000321,000-433,000-2,701,000-8,763,000-14,094,000-12,560,000-16,464,000-14,267,00011,284,000-52,638,000-49,410,000-19,376,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
URL
https://www.codexis.com/
IPO date
Apr 22, 2010
Employees
248
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT